Tafasitamab plus acalabrutinib and obinutuzumab for untreated CLL/SLL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 study tests a new combination of medicines to treat people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has not been treated before and needs therapy. It aims to shrink the disease and control it safely in this early testing stage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can sign consent (or your legal representative can).
- You have a confirmed new diagnosis of CLL or SLL with test results from blood flow testing or a lymph node biopsy.
- Your body must be able to take and keep oral (swallowable) study medicine.
- Your leukemia/lymphoma must meet at least one “needs treatment” sign (for example, worsening anemia/low platelets, big/symptomatic spleen or lymph nodes, or specific symptom patterns).
- If you have SLL only: your scans must show measurable swollen lymph nodes of certain sizes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether acalabrutinib, and optionally adding obinutuzumab, can control early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to see how well these treatments work and how safe they are in people who have not had prior treatment.
This trial tests whether combining three drugs (tafasitamab, acalabrutinib, and venetoclax) can better treat chronic lymphocytic leukemia or small lymphocytic lymphoma in patients who haven't received prior treatment. The goal is to see if this combination helps control the disease and improve outcomes.
This Phase 2 trial studies how well acalabrutinib works when combined with either venetoclax or obinutuzumab in people with untreated chronic lymphocytic leukemia (CLL). It aims to improve disease control while checking safety and tolerability.
This study tests acalabrutinib together with obinutuzumab in people with newly diagnosed chronic lymphocytic leukemia (CLL) to see how well the combination works. It may help by improving control of the cancer, but you’ll be closely monitored for side effects.
This trial tests two different combinations of targeted drugs for people with CLL or SLL who have not had prior treatment for their disease. The goal is to see if these combinations are safe and effective.
This trial tests a combination of two targeted drugs, zanubrutinib (a pill) and obinutuzumab (an infusion), for people with untreated CLL or SLL who need treatment. The goal is to see if this combination works well and is safe.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.